Equities

Forecasts data is unavailable for this security.

Consensus recommendation

As of Sep 22, 2017, the consensus forecast amongst 25 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform8
Hold12
Underperform0
Sell0

Share price forecast

The 18 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 82.50, with a high estimate of 96.00 and a low estimate of 61.00. The median estimate represents a -0.92% decrease from the last price of 83.27.
High15.3%96.00
Med-0.9%82.50
Low-26.7%61.00

Dividends

In 2016, Gilead Sciences Inc reported a dividend of 1.84 USD, which represents a 42.64% increase over last year. The 11 analysts covering the company expect dividends of 2.12 USD for the upcoming fiscal year, an increase of 15.11%.
Div growth (TTM)42.64%
More ▼

Earnings history & estimates

On Jul 26, 2017, Gilead Sciences, Inc. reported 2nd quarter 2017 earnings of 2.56 per share. This result exceeded the 2.15 consensus of the 19 analysts covering the company and under-performed last year's 2nd quarter results by 16.88%.
The next earnings announcement is expected on Oct 30, 2017.
Average growth rate-3.79%
Gilead Sciences, Inc. reported annual 2016 earnings of 11.57 per share on Feb 07, 2017.
Average growth rate+87.20%
More ▼

Revenue history & estimates

Gilead Sciences, Inc. had 2nd quarter 2017 revenues of 7.14bn. This bettered the 6.37bn consensus of the 16 analysts covering the company. This was 8.17% below the prior year's 2nd quarter results.
Average growth rate-1.83%
Gilead Sciences, Inc. had revenues for the full year 2016 of 30.39bn. This was 6.89% below the prior year's results.
Average growth rate+40.47%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.